Gina Mauro | Authors

Treatment With Adjuvant Atezolizumab Yields Improved Outcomes in Stage II-IIIA PD-L1–Positive NSCLC

September 20, 2021

Patients with stage II to IIIA non–small cell lung cancer experienced an improvement in disease-free survival and time to locoregional and distant relapse after being treated with adjuvant atezolizumab.

Patients With Frontline Gastric/GEJ Cancers Benefit When Nivolumab Is Added to Chemotherapy

September 19, 2021

Data presented at 2021 ESMO show that nivolumab plus chemotherapy improves survival outcomes in certain patients with frontline gastrointestinal cancers, but not nivolumab plus ipilimumab.

Trastuzumab Deruxtecan Yields Robust Antitumor Responses in HER2+ NSCLC

September 18, 2021

Patients with HER2-mutated non–small cell lung cancer derived robust and long-lasting responses from fam-trastuzumab deruxtecan-nxki.

Western Patients With HER2-Positive Gastric/GEJ Cancers Demonstrate Promising Responses to Trastuzumab Deruxtecan

September 18, 2021

Updated results of DESTINY-Gastric02 trial show antitumor response with trastuzumab deruxtecan in patients with in certain patients with HER2-positive gastric/gastroesophageal junction.

Response to Immunotherapy in Prostate Cancer Correlates With MSI-H/dMMR

September 18, 2021

An analysis of patients with prostate cancer treated with immune checkpoint blockade indicated that microsatellite instability and mismatch repair may be indicative of response.

Adding Carboplatin to Neoadjuvant Paclitaxel Improved Outcomes in TNBC

September 18, 2021

Although the addition of carboplatin to neoadjuvant paclitaxel followed by cyclophosphamide helped to improve outcomes for those with treatment-naïve triple-negative breast cancer, the addition of veliparib did not have an impact on pathologic complete response or event-free survival.

Pirtobrutinib Yields Promising Responses in Previously Treated CLL/SLL

September 13, 2021

Patients with previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma appeared to benefit from treatment with pirtobrutinib.

Talquetamab Yields Promising Phase 1 Data in Relapsed/Refractory Multiple Myeloma

September 12, 2021

Patients with relapsed/refractory multiple myeloma who were treated with the recommended phase 2 dose of talquetamab experienced positive clinical activity.

Pirtobrutinib Demonstrates Strong Response Rates for Previously Treated CLL/SLL

September 11, 2021

Strong response rates were observed with pirtobrutinib across dose levels to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma ion a phase 1/2 study.

Durvalumab and Chemotherapy, Plus or Minus Tremelimumab Yields Survival Benefit in Frontline Treatment of Advanced NSCLC

September 09, 2021

The phase 3 POSEIDON trial indicated that patients with metastatic non–small cell lung cancer who were treated with first-line durvalumab and chemotherapy with or without tremelimumab experienced a statistically significant survival benefit.